Praxis und Abteilung für Urologie

Klinik am Ring
Hohenstaufenring 28
50674 Köln

Tel.: 0221-92424-450
Fax: 0221-92424-460
Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

Studie zum PSMA-PET/CT
Seit 2014 setzt das Westdeutsche Prostatazentrum den neuen PSMA PET-Marker in Kooperation mit der Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Köln ein. Hier eine aktuelle Studie beider Institutionen zum PSMA PET/CT. Das Abstract können Sie sich hier anschauen.
60. Jahrestagung der Deutschen Gesellschaft für Urologie in Stuttgart
Vom 24. bis 27.09.2008 trafen sich namhafte Experten in Stuttgart und diskutierten über den aktuellen Stand der Diagnostik und Therapie urologischer Erkrankungen. Einen Schwerpunkt des wissenschaftlichen Programms stellte die Therapie des Prostatakarzinoms dar. Auch Dr. Neubauer und Dr. Derakhshani präsentierten einem breiten Publikum ihre aktuellen Daten.

Die Abstracts können Sie sich hier anschauen:
Prospektive Erfassung von Lebensqualität und Toxizität der HDR-Brachytherapie als interstitieller Boost bei der Behandlung des Prostatakarzinoms Mehr

Prospektive Analyse der langfristigen gesundheitsrelevanten Lebensqualität nach definitiver LDR-Brachytherapie der Prostata Mehr

Rezidivfreies Überleben und dosimetrische Ergebnisse von Patienten mit lokal begrenztem Prostatakarzinom nach interstitieller 125-Iod-LDR-Brachytherapie Mehr

2008 World Congress of Brachytherapy in Boston
Vom 4.-6. Mai 2008 fand in Boston der Weltkongress für Brachytherapy der Amerikanischen und Europäischen Strahlentherapiegesellschaften statt. Auf diesem weltgrössten Meeting für die modernste Form der Strahlentherapie diskutieren rund 1000 Experten über den aktuellen Stand der Prostatatherapie. In diesem Jahr war das Team des Westdeutschen Prostatazentrums mit vier Veröffentlichnungen vertreten. Dr. Derakhshani und Dr. Neubauer präsentierten mit dreii Vorträgen und Postern die Kölner Daten.

Parallel dazu fand der Jahreskongress der Deutschen Gesellschaft für Strahlentherapie in Wien statt, auf dem Dr. Spira und Dr. Weise die Erfahrungen des Kölner Teams vor dem Auditorium präsentierten.

Alle Abstracts finden Sie hier:
Interstitial low-dose-rate mono-brachytherapy with I125 - relapse-free survival and dosimetric outcome for localised prostate cancer in a single European institution Mehr

Prospective analysis of long-term health-related quality-of-life after permanent brachytherapy for prostate cancer Mehr

Prospective study on quality-of-life and toxicity of high-dose-rate brachytherapy as an interstitial boost for localized prostate cancer. Mehr

HDR boost (real time) in patients with localized prostate cancer: technical description and preliminary results Mehr

Abstracts der aktuellen Publikationen

Prostate Brachytherapy - State of the Art (Zusammenfassung)
Iodine-125 prostate brachytherapy in localized prostate cancer: importance of team experience for dose delivery and toxicity

Prostate Brachytherapy
Im Herbst 2005 fand in Speyer unter Beteiligung des Westdeutschen Prostatazentrums ein Konsens-Meeting zum aktuellen Stand moderner Formen urologischer Therapien statt. Es nahmen Experten der deutschen Urologie teil - der Konsens und aktuelle State-of-the-Art wurde in einem Buch zusammengefasst und im Thieme-Verlag veröffentlicht.

Das Buch "Therapeutic Energy Applications in Urology" ist in Deutschland unter der ISBN 3-13-134171-8 und in den USA unter ISBN 1-58890-428-8 zu bestellen.

Einen Sonderdruck des State-of the-Art Artikels "Prostate Brachytherapy" mit Tabellen, Abbildungen und Literaturverzeichnis können Sie gerne per Mail bei uns anfordern.
Sonderdruck anfordern

Eine Zusammenfassung des Textes finden Sie nachfolgend zum Ausdrucken.

Prostate Brachytherapy
Neubauer S., Derakhshani P., Spira G.

Brachytherapy is a form of radiation therapy in which a radiation source is placed either within or in close proximity to the tissue. In low dose prostate brachytherapy, radionuclide sources are permanently implanted into the prostate gland, in high-dose rate brachytherapy the source is temporarily introduced into the prostate and removed after radiation treatment.
Developments in transrectal ultrasound, the use of a transperineal approach instead of retropubic implantation and the enormous advances in planning software renewed the interest in prostate brachytherapy and led to an increasing use worldwide.
Physical advantages of brachytherapy result from the fact that radioactive sources are located within the target volume; thus, the distance radiation has to travel through tissue to reach its target is minimised. Prostate tumors can be treated without radiating the skin or other dose-limiting organs. A second advantage is attributable to the “inverse square” law. The intensity of radiation decreases proportionally to the inverse of the square of the distance between source and target. Because of this exponential attenuation of radiation intensity, the dose decreases at a much greater rate near the radioactive source compared to external radiation techniques. With judicious source placement very high doses can be delivered to the tumor, and a minimum dose given to adjacent normal structures.
Several studies have shown the importance of physician experience for adequate dose delivery , .
At least 100 initial treatments and approximately 40-60 annual procedures will be necessary for every team to achieve high and reproducible implant quality.

Modern prostate brachytherapy technique
In 1981, Holm in Denmark developed a transperineal implant method using transrectal ultrasound (TRUS) . TRUS was used to guide percutaneous delivery of radioisotopes, achieving uniform seed distribution in the prostate and eliminating the guesswork previously used to guide the seeds in place. This formed the basis of the transperineal technique that today is used in brachytherapy, whether it is permanent or temporary, high-dose rate (HDR), or low-dose rate (LDR) brachytherapy.
The aim of permanent seed implants (PSI) is to deliver a tumoricidal dose to the entire prostate gland. The seeds employed may contain either the radio-isotope iodine125 or palladium103. The seeds are introduced into the prostate gland by means of template-guided needles transperineally under transrectal ultrasound guidance. Dose planning software permits rapid planning of the seed position and dose profiles around the prostate capsule to ensure that an adequate dose is achieved around the periphery of the gland together with a suitable margin. At the same time calculations are made to assure that adjacent organs receive as little dose as possible in order to limit side effects. Implant techniques vary from preloaded needles to afterloading the seeds once the needles are introduced into the gland. Stranded seeds are used preferably over loose seeds to prevent seed migration and improve post implant dosimetry.
At present most centres use an intraoperative technique, where planning and execution of the implant are done in a single session. A report from The American Brachytherapy Society in 2000 recognised the following variations
Preplanning: Creation of a plan a few days or weeks before the implant procedure.
Intra-Operative Planning: Treatment planning in the operating theatre; the patient and TRUS probe
are not moved during the time between the volume study and seed insertion procedure.
Intra-Operative Preplanning: Creation of a plan in the operating theatre just before the implant procedure, with immediate execution of the plan.
Interactive Planning: Stepwise refinement of the treatment plan using computerised dose calculations derived from image-base needle position feedback.
Dynamic Dose Calculation: Constant updating of calculations of dose distribution using continuous deposited seed position feedback.
After the seeds are implanted, a post implant dosimetry is performed as a quality control measure to ensure that the dose delivered to the gland has been sufficient.
The influence on treatment efficacy of the technical modifications described above remains unclear at present.

In temporary prostate implants (TPI), afterloading needles are placed under ultrasound guidance into the prostate. A dose calculation based on ultrasound or CT-scan images is performed. The radioactive sources are loaded into the needles according to the treatment plan only for the duration of the procedure. Optimized inverse planning provides greater flexibility for delivering individual dose distributions. A remote afterloading unit under robotic control is used to deliver treatments. This minimizes the radiation exposure to medical staff. A single radioactive source is moved along the afterloading needles. After the target dose is delivered, the source and the needles are removed. Recently intraoperative realtime planning has also been introduced to TPI.37 The possibility of realtime-modification in conjunction with ultrasound-based image acquisition in 1 mm slices enhances implant quality possibly leading to improved clinical results in the future.

Patient selection for brachytherapy
Prostate brachytherapy is a multidisciplinary technique. Patient selection involves issues that relate to both urology and radiation oncology. The most commonly used risk stratification criteria appear in table 1. In accordance with the recommendations of the American Brachytherapy Society and the EAU/ESTRO/EORTC , patients with low risk prostate cancer may be treated with PSI alone. There are a number of studies that have shown good results with PSI alone or combined with external beam radiotherapy (EBRT) in patients with intermediate risk disease. An RTOG study, now closed, randomised patients with intermediate risk disease to implant alone or implant combined with external beam radiotherapy, the results although pending should help to clarify the optimal treatment strategies for these patients.

For high risk patients the role of brachytherapy is less certain. Patients with two or more adverse risk factors (PSA > 10 ng/ml, Gleason score > 6 or > T2a disease) are frequently treated with EBRT for 5 weeks before or after the implant. Despite these general guidelines, some experts believe that as long as an adequate margin is applied to the target volume there is no need for EBRT, whereas others routinely recommend the use of external beam in combination with brachytherapy.

Technical Considerations
For PSI prostate size is optimal below 50 ml to avoid pubic arch interference. In experienced hands, larger prostates up to 70 ml volume can safely be treated if pubic arch interference is ruled out and IPSS is below 15. Volume reduction with an LHRH analogue may be indicated, if the pubic arch is narrow , however these patients have been shown to have a higher incidence of post implant retention and irritative symptoms . Patients must be able to flex their hips to 90º, have a pre-treatment IPSS of <15, a maximum urinary flow rate above 10 ml/s and should be clinically or urodynamically unobstructed , . Prior transurethral resection of the prostate (TURP) is a relative contraindication to PSI, especially if there is a large or irregular resection defect or continence is marginal. Time interval between TURP and seed implant should be at least 6 months to avoid substantial urinary morbidity , . With strict patient selection, PSI can be safely performed in patients after TURP.

As temporary implants do not cause prolonged radiation, urinary morbidity in general is lower in patients at risk (prior TURP, large prostate volume, high IPSS) . Therefore patients not suitable for permanent implants in terms of urinary tract status may be candidates for a temporary implant instead.

Clinical Results
Permanent Seed Implant Monotherapy
Long term results have been reported in the literature by many centres around the world. The first to publish 10 year results were the Seattle group in 1998 . This series was comprised of the first cohort of patients ever treated with modern brachytherapy techniques. Risk stratification in patient selection was not well understood at the time. Of 152 patients in the series, 64% were treated with implant alone. Thirty six percent, who were deemed at higher risk, were treated with a combination of implant (Iodine125 or Palladium103) and external beam radiotherapy. Biochemical disease free survival (PSA < 0.5 ng/ml) at 10 years was 64%. The effect of the learning curve for the technique and the treatment in general could be appreciated when in 2001, the same group published results for low risk patients treated two years on1. There was a significant improvement in the results, 87% of patients treated had biochemical disease free survival (PSA 0.2 ng/ml) at ten years follow up.

Other centres, both in America and Europe, have produced similar long term results as shown in tables 2 and 3.

Combined Permanent Seed Implant and EBRT
There are a number of publications on long-term follow-up of patients with intermediate and high risk prostate cancer treated with PSI. Most authors advocate combined treatment with EBRT, although some authors reported similar results with PSI monotherapy 14, 15, 16, . To date it remains unclear whether high risk tumors can be treated with PSI alone or need combined treatment. At present it seems reasonable to treat patients with intermediate risk tumors with PSI monotherapy in selected cases.

Stock el al31 treated 132 high-risk patients (Gleason score 8-10, PSA level >20 ng/ml, Stage T2c-T3 or positive seminal vesicle biopsy or two or more of the following: Gleason score 7, PSA level >10-20 ng/ml, or Stage T2b) with combined hormonal therapy (9 months), permanent radioactive seed brachytherapy, and external beam radiation. The actuarial overall freedom from PSA failure rate was 86% at 5 years. (97% /85% /76% for Gleason <6/ 7/ 8-10).

Merrick et al reported on 46 consecutive T1c-T2b (1997 AJCC) patients with Gleason score 8 and 9 prostate cancer with a median follow-up of 58 months treated with Pd-103 and supplemental external beam radiation therapy (45 Gy). The utilization of hormonal therapy for 6 months or less resulted in a statistically not significant improvement in biochemical outcome (92.3% versus 81.8%, P = 0.393).

Critz et al 12 treated 1.469 men (T1,T2,Nx,M0) with PSI followed by external irradiation with a median follow-up of 6 years. The overall 10-year disease-free survival rate (PSA < 0.2 ng/ml) was 83%. Median time to recurrence was 30 months (range 3 months to 8 years) and 24% of recurrences were after 5-year follow-up. 10-year DFS for low, intermediate and high risk group was 93%, 80% and 61%, respectively (p <0.0001). Pre-treatment PSA, Gleason score and percent

Zurück zur Übersicht

Abstracts der aktuellen Publikationen

Iodine-125 prostate brachytherapy in localized prostate cancer: importance of team experience for dose delivery and toxicity.
Neubauer S1,2, Derakhshani P1,2, Metz J1,3, Spira G1,3
(1) West German Prostate Center, Cologne, Germany
(2) Department of Urology, Klinik am Ring, Cologne
(3) Department of Radiooncology, Klinik am Ring, Cologne

Background and purpose:
In transperineal permanent prostate brachytherapy with I-125 adequate radiation doses are required for good clinical results. Moreover permanent seed implantation is a highly operator-dependent procedure with a frequence-related learning curve. After 3 years of seedimplantation in a constant team of four physicians (two urologists and two radiooncologists) the purpose of the present report is to determine whether dosimetric quantifiers of implant adequacy, OR-time and postoperative toxicity were affected by the experience of the implantation team.
Materials and methods:
Between February 2001 and January 2004, 518 consecutive patients were treated with permanent seed implants using iodine RAPID-strands and intraoperative online planning technique (IOT). 461 low risk patients were treated by seedimplant alone and 57 intermediate and high-risk patients recevied an additional external beam therapy. Dosimetric quantifiers (DQ) of implant adequacy were calculated using a computed tomography (CT) scan performed 1 month following prostate brachytherapy. Urinary toxicity was measured with IPSS and QoL-scores. Patients were divided into group 1:implants number 1-259 and group 2: implants number 260-518. Groups were compared regarding preoperative and postoperative IPS-Scores and achieved dosimetric quantifiers pre- and postoperatively.
Patients in group 1 had a lower mean D90 to the prostate compared to men in group 2 (144.13 Gy vs. 152.26 Gy). Toxicity was very similar in both groups: mean IPPS in group 1 at 0/1/3/6/12 months after treatment being 6.7/14.6/13.6/10.5/7.5 compared to group 2 (7.3/15.4/14.3/10.7/8.3). Mean procedure duration including online-planning, needle-loading and implantation was reduced from 112 (57-183) minutes in group 1 to 66 (34-82) minutes in group 2. Urinary toxicity in combined treatment was not higher compared to seed implant alone.
There were no major differences in early and latter seed implants in terms of urinary toxicity. Quality of dose distribution was improved markedly with increased experience. Maybe because we used the intraoperative online planning technique (IOT) from the first case on and had no changes in the team constellation differences were smaller than expected and reported earlier.

Zurück zur Übersicht

Influence of intraoperative Prostate Volume on early Urinary Toxicity after permanent Prostate Brachytherapy
Derakhshani P1,2, Neubauer S1,2, Metz J1,3, Spira G1,3
(1) West German Prostate Center, Cologne, Germany
(2) Department of Urology, Klinik am Ring, Cologne
(3) Departement of Radiooncology, Klinik am Ring, Cologne

Background and purpose:
Significant enlargement of the prostate results in a higher average number of seeds used in permanent seed implants (PSI) of localized prostate cancer. We determined wether the prostate volume on intraoperative online dosimetry affects postoperative urinary toxicity as measured by IPSS, Qol-score and urinary complications.
Materials and methods:
Between Feb. 2001 and Jan. 2004 518 consecutive patients were treated in a single institution with permanent seed implants using iodine seeds (RAPID-strands). Seeds were placed under realtime US guidance in a modified peripheral loading technique for all prostate sizes. Patients were stratified in three groups based on their intraoperative prostate volume (PV): Group 1 with a PV < 20 cc, group 2 with a PV of 20-40 cc and group 3 with a PV > 40 cc. Patients completed the IPSS-questionnaire and Qol-Score before treatment and at 1, 3, 6 and 12 months after treatment. All patients were followed concerning urinary complications.
PV in all patients ranged from 8 to 74 cc. Group 1 (small PV) consisted of 126 patients, group 2 (midsize PV) consisted of 313 patients and 64 patients were assigned to group 3 (large PV). Mean number of seeds used was 31.9 (group 1), 44.7 (group 2) and 63.1 (group 3). Pre-treatment IPSS was similar in groups 1/2 (mean 6.29 and 6.87) and higher in large PV (mean 9.32). Group 1: IPSS increased during radiation to means of 13.3, 12.9, 9.3 and returned almost to baseline after 12 months (mean 6.9). Group 2 showed similar results with a slower decrease to almost baseline (mean 15.2, 14.1, 10.9 and 7.5 at 12 months). In group 3 mean IPSS were 18.3, 15.1 and 12.6 during radiation and returned to baseline after 12 months (mean 9.8). Mean pre-treatment Qol-scores stratified by groups were 1.1, 1.3 and 1.8. In all groups scores increased during radiation to 2.4, 2.6 and 3.2 and fell to baseline after 12 months in groups 1 and 2 (1.1 and 1.2). In group 3 mean QoL-score remained slightly increased at 2.0 after 12 months.
Although number of utilized seeds, total activity applied and pretreatment urinary function differed between small, midsize and large volume prostates, urinary toxicity as measured by IPSS an QoL did not differ between groups. Implantation of prostates larger than 40 cc did not result in worsened urinary function as compared to smaller glands. We therefore do not routinely recommend neoadjuvant downsizing in larger prostates unless there is evidence of pubic arch interference.

Zurück zur Übersicht

Quality of dose distribution with realtime-plan-modification (RPM) in permanent seed implants
Derakhshani P1,2, Neubauer S1,2, Metz J1,3, Spira G1,3
(1) West German Prostate Center, Cologne, Germany
(2) Department of Urology, Klinik am Ring, Cologne
(3) Departement of Radiooncology, Klinik am Ring, Cologne

Background and purpose:
Standard procedure for quality assurance in permanent seed implants has been a CT-scan based postplanning 4-6 weeks after treatment. Realtime-plan-modification offers the chance to adopt the plan immediately to intraoperative changes in seed position or prostate volume and shape. We determined wether this leads to superior planning and implantation accuracy.
Materials and methods:
Between Jun. 2002 and Jan. 2004 317 consecutive patients were treated in a single institution with permanent seed implants using iodine seeds (RAPID-strands) as monotherapy in low-risk localized prostate cancer. Intraoperative online-planning was performed. Seeds were placed under real-time US guidance in a modified peripheral loading technique with preloaded needles. The acutal US image was fusioned with the preplan. A realtime-plan modification according to the actual seed positions after each implanted needle was calculated using the Variseed 7.0 planning system. Seed positions were corrected to the actual US image in X,Y and Z-axis. The dosimetry results were analyzed after full dose iodine-implantation.
An average number of 45 seeds implanted with 17 needles were used. Mean seed activity was 0.60 mCi (range 0.46-0.68). Intraoperative preplanning was achieved with the dosimetry results: mean D90 prostate 173,3 Gy (range 113-194 Gy), mean V100 prostate 97.75% (range 91.29-100%), mean D10 urethra 196.74 Gy (range 138.50-219.32 Gy), mean D30 rectum 80.9 Gy (range 31.48-121.79 Gy). In realtime-plan-modification dosimetry values did not change significantly (means: D90 prostate 172.0 Gy, mean V100 prostate 97.40%, mean D10 urethra 197.42 Gy, mean D30 rectum 79.76 Gy). Actual seed positioning did not reduce quality of dose distribution. In postplanning CT-scan values were: mean D90 prostate 152.7 Gy and V 100 prostate 92.2% as mean value. Dosimetry criteria of the ABS were fulfilled in all but four cases. In those four cases with isolated cold spots additional 4 to 7 seeds were placed immediately after postplanning results.
Differences in actual seed position and changes in prostate size compared to the intraoperative preplan did not result in worse dosimetry results, when realtime-modified planning was utilized. This tool is able to detect implant weakness during implant, enabling the physicians to adjust for dosimetry values.

Zurück zur Übersicht

Catheter Reconstruction in TRUS-guided interstitial prostate HDR-brachytherapy under Realtime-guidance with the Planning System "Swift"
Spira G1,2, Metz J1,2, Muskalla K1,2, Derakhshani P1,3, Neubauer S1,3
(1) West German Prostate Center, Cologne, Germany
(2) Department of Radiooncology, Klinik am Ring, Cologne
(3) Departement of Urology, Klinik am Ring, Cologne

PURPOSE: Reconstruction of the application needles during intraoperative planning process is the most challenging and technically diffcult part in HDR-afterloading. Slight deviations between actual and reconstructed positions of each needle can lead to serious differences of calculated and definitive dose delivery, especially in implantation techniques without template reconstruction. We describe the graphical capabilities of the new 3D-planning system "Swift" for transrectal ultrasound-planned realtime conformal HDR-brachytherapy in localized prostate cancer.
PATIENTS AND METHODS: After having used the “Abacus” and the “Brachyvision”-planning systems in 143 patients (429 procedures) between June 2000 and March 2003 we treated 61 patients (189 procedures) with a pelvic EBRT (50.4 Gy) interdigitated with transrectal ultrasound-guided real-time HDR-brachytherapy boost using the "Swift"-system (Nucletron) between April 2003 and January 2004. Ultrasound-accquisition was performed in 1mm-slices by use of an electronic encoder in the stepping-unit. Median number of TRUS images acquired was 79. The treatment planning was performed using the new "Swift" planning system, which presents ultrasound images in transversal, coronary and sagital planes simultaneously. The system gives a real-time-image during needle reconstruction, thus improving accuracy of reconstruction. Implant quality was assessed via dose-volume histograms (DVH).
RESULTS: Concerning ASTRO-criteria 10 patients were in the low risk group, 18 patients had an intermediate risk and 33 had a high risk tumor. Fractions were 7.5 Gy per session in three weekly sessions. 2 patients received HDR-monotherapy using 4 fractions of 8 Gy in a salvage therapy setting after failure of surgery/3D conformal radiotherapy. Median volume of the prostate was 28.6 cc (12.5 – 87.6). In all patients “free-hand technique” needle placement, without use of a template, was used to obtain ideal conformal dose distribution in accordance to a “peripheral loading technique”. Median applicator number was 10.7. Mean D90 prostate was 103% (range 66-118%), mean V100 prostate was 94% (range 70-100%). Using the new system average time for needle reconstruction and treatment planning could be reduced to 23.6 minutes.
CONCLUSION: 3-D-reconstruction of applicator needles is simplified by the graphical presentation tools of the plannig system Swift. In consequence OR-time can be reduced. These initial results, the low rate of complications and lack of permanent radioactive implants encourage us to further follow this treatment option. Late toxicity and tumor control rates will be reported as longer follow-up allows.

Zurück zur Übersicht

Einfluss der Dosisverteilung auf die Lebensqualität nach permanenter Seedimplantation
Derakhshani P1, Spira G2, Kacpura W2, Neubauer S1

(1) Abteilung für Urologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln
(2) Abteilung für Radioonkologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln

Wir berichten über den Einfluss der Dosisverteilung auf allgemeine und prostata-spezifische QoL nach permanenter Seedimplantation (PSI).
Zur Auswertung kommen die Daten von 328 konsekutiven Patienten (04/2004 bis 12/2005) mit PSI bei low-risk Prostatakarzinom. Erfasste Dosis-Parameter waren Prostatavolumen, Seed- und Nadelzahl, V100-Prostata, D90-Prostata, D30-Urethra und D10-Rektum. Vor der Behandlung sowie zu den Zeitpunkten 3, 6 und 12 Monate nach der Behandlung erhalten alle Patienten einen validierten Fragebogensatz bestehend aus EORTC-QLQ-C30 mit Prostatamodul PR25, IIEF5 sowie IPSS der AUA.
Die Parameter zu Miktion und Darmfunktion im PR25 fielen zu den Zeitpunkten 3 und 6 Monate nach Implantation signifikant schlechter aus als vor der Behandlung. Nach 12 Monaten zeigte sich kein signifikanter Unterschied mehr. In der Regressionsanalyse bestand für die Miktion nach 3 Monaten eine signifikante Korrelation zu Volumen und Seedzahl. Für die Darmfunktion nach 3 Monaten zeigte sich eine signifikante Korrelation zur V100-Prostata der Nachplanung. Die Sexualfunktion und allgemeine QoL waren im Beobachtungszeitraum nicht signifikant beeinträchtigt. Signifikante Unterschiede gegenüber dem Ausgangs-IPSS (7,05) fanden sich nach 3 (14,64), 6 (13,89) und 12 (8,01) Monaten. In der Regressionsanalyse fand sich ein Zusammenhang von IPSS nach 6 Monaten zu Nadelzahl und D30-Urethra.
Die permanente Seedimplantation ist eine gut verträgliche und etablierte Behandlungsoption bei lokal-begrenztem Prostatakarzinom. Die QoL war in den Bereichen Miktion und Darmfunktion beeinträchtigt, kehrte jedoch nach 12 Monaten wieder auf Ausgangsniveau zurück.

Zurück zur Übersicht

Einfluss der Urethraldosis auf die therapieinduzierte Dysurie nach permanenter Seedimplantation bei lokal begrenztem Prostatakarzinom
Spira G1 Derakhshani P2 Kacpura W1 Neubauer S2

(1 Abteilung für Radioonkologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln
(2 Abteilung für Urologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln

Die Dysurie ist bei der permanenten Seedimplantation (PSI) des Prostatakarzinoms häufigste Nebenwirkung und wichtiger Einflussfaktor auf die postoperative Lebensqualität. Wir untersuchten die prognostische Aussagekraft des Dosisparameters D30-Urethra für die postoperative Dysurie.
Patienten und Methode:
Im Zeitraum 02/2001 bis 6/2005 wurden 737 konsekutive Patienten im klinischen Stadium T1c-T2a mittels PSI behandelt. Als primärer Qualitätsparameter für die Dosisverteilung wurde eine D90-Prostata von mehr als 140 Gy festgelegt.
Die Patienten wurden anhand der D30-Urethra eingeteilt: Gruppe 1 D30 <195 Gy (33,5%), Gruppe 2 196 Gy bis 210 Gy (52,4%) und Gruppe 3 > 210 Gy (14,1%). Der IPSS wird vor Therapie und nach 3/6/12/18/24/36 Monaten erhoben. Dysurie wurde definiert als eine Verschlechterung des IPSS um mehr als 4 Punkte. Als Normalisierung wurde das Erreichen des Ausgangswertes plus 1 definiert.
Das mittlere Follow-Up beträgt 33,4 Monate. 85,9% (n= 633) aller Patienten konnten mit einer D90 von mehr als 140 Gy behandelt werden. Die mediane D30-Urethra betrug 201,4 Gy. Zum Zeitpunkt 6 Monate nach Behandlung war bei 38,6% der Gruppe 1, 65,1% der Gruppe 2 und 12,5% der Gruppe 3 der IPSS wieder normalisiert (Baseline+1). Die Inzidenz der Dysurie über alle Gruppen betrug nach 1 Monat 56,6%, nach 3 Monaten 53,9%, nach 6 Monaten 48,1% und nach 12 Monaten 14,5%.
Die Auswertung der Patienten nach Baseline-IPSS (< bzw. >12 Punkte) zeigte keinen signifikanten Unterschied nach 6 Monaten (62,8% vs. 64,1% Normalisierung).
Im Gegensatz zur D30-Urethra erlaubt der prätherapeutische IPSS keine prognostische Aussage für den Zeitpunkt bis zur Normalisierung der Miktion. Neben dem in der Literatur häufig genannten Risikofaktor Prostatavolumen spielt die verabreichte Urethraldosis eine wichtige Rolle für die Miktionsqualität nach PSI.

Zurück zur Übersicht

Qualität der Dosisverteilung bei der realtime-modifizierten Dosisplanung der permanenten Seedimplantation
Neubauer S1, Spira G2, Kacpura W2, Derakhshani P1

(1) Abteilung für Urologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln
(2) Abteilung für Radioonkologie, Westdeutsches Prostatazentrum, Klinik am Ring, Köln

Einleitung und Zielsetzung:
Bei der LDR-Brachytherapie zeigen sich signifikant höhere Raten an biochemischer Rezidivfreiheit bei einer D90-Prostata>140Gy. Die realtime-modifizierte Dosisplanung (RPM) bietet die Möglichkeit den Dosisplan sofort an intraoperative Verschiebungen der Seedposition anzupassen. Wir untersuchten Dosisplanung und Implantationsparameter unter RPM.
Seit Einführung der Realtime-Planung wurden zwischen 10/02 und 12/05 689 konsekutive Patienten mit PSI behandelt. Die Seeds wurden in einer modifizierten peripheren Beladungstechnik platziert. Das aktuelle Ultraschallbild wurde mit der intraoperativen Dosisplanung fusioniert. Eine RPM wurde anhand der realen Seedposition nach jeder Nadel vorgenommen.
Bei einem intraoperativen Prostatavolumen von 31,6 ml (11 – 88) wurden im Mittel 45 Seeds über 17 Nadeln implantiert. Die intraoperative Dosisplanung ergab folgende mittlere Dosisparameter: D90-Prostata 175,85 Gy (Range 133-194 Gy), V100-Prostata 97,56% (Range 90-100%), D30-Urethra 198,53 Gy (Range 158-227 Gy), D10-Rektum 88,55 Gy (Range 34-129 Gy). In der RPM veränderten sich die mittleren Dosisparameter nicht signifikant (D90-Prostata 176,67 Gy, V100-Prostata 97,40%, D30-Urethra 198,94 Gy, D10-Rektum 85,89 Gy). Die reale Umsetzung des Dosisplans führte unter RPM somit nicht zu einer Verschlechterung der Dosisverteilung. Die von der American Brachytherapy Society (ABS) geforderten Dosisparameter wurden in vier Fällen nicht erreicht. In diesen vier Fällen mit isolierten “Cold-Spots” wurden vier bis sieben zusätzliche Seeds nachimplantiert.
Veränderte Seedpositionen im Vergleich zur intraoperativen Vorplanung führten bei Verwendung einer RPM nicht zu einer Verschlechterung der Dosisparameter. Die Echtzeit-Modifikation ist in der Lage Implantationsschwächen aufzudecken und gibt dem Behandler die Möglichkeit diese intraoperativ auszugleichen.




mdc plakette 9001 d1  focus2017




Prostatakrebs-Rezidiv: Strahlentherapie mit Hormontherapie kombinieren

Patienten mit einem Rezidiv profitieren von einer Kombination aus Strahlen- und Hormontherapie

US-Expertengremium empfiehlt erneut PSA-Test zur Früherkennung
Deutliche Abnahme der Sterblichkeit und Metastasierung bei PSA-getesteten Männern
Kein Nachteil durch verzögerten Therapiebeginn

Patienten mit lokalisiertem Prostatakarzinom  sollten sich bei der Therapiewahl nicht unnötig unter Zeitdruck setzen lassen

PSMA-PET/CT: Lokalrezidiv oder metastasierter Tumor?

CHAPPP:Studie: PSMA PET/CT zeigt höhere Empfindlichkeit gegenüber Metastasen

Focus-Arztempfehlung für Dr. Stephan Neubauer

Dr. Stephan Neubauer wird von FOCUS-GESUNDHEIT gleich zweimal als TOP-Mediziner empfohlen.

Go to top